13019-32-4

Basic information

• Product Name: 7-Bromoquinolin-8-ol
• Synonyms: 7-Bromoquinolin-8-ol;7-BroMo-8-hydroxyquinoline;7-BroMo-8-hydroxyquinoline 97%;7-bromo-8-Quinolinol
• CAS NO: 13019-32-4
• Molecular Formula: C₉H₆BrNO
• Molecular Weight: 224.06
• Mol File: 13019-32-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 140-142℃
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 7-Bromoquinolin-8-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromoquinolin-8-ol(13019-32-4)
• EPA Substance Registry System: 7-Bromoquinolin-8-ol(13019-32-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26
• WGK Germany: 1
• Hazardous Substances Data: 13019-32-4(Hazardous Substances Data)

Usage

General Description

7-Bromoquinolin-8-ol, also known as 8-Hydroxy-7-bromoquinoline, is a chemical compound with the molecular formula C9H6BrNO. It is a yellow to brown crystalline powder with potential applications in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a building block in organic synthesis and as a research chemical for various scientific investigations. Additionally, 7-Bromoquinolin-8-ol has been studied for its potential biological activities, including as an antimicrobial, antifungal, and antitumor agent. Its properties and potential applications make it a valuable compound in the field of chemical and pharmaceutical research.

Upstream product

• 148-24-3 8-quinolinol 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 10218-87-8 N-Brom-methylbutylamin 

Downstream Products

• 422550-68-3 (3-benzyl-phenyl)-(8-methoxy-ethoxymethoxy-quinolin-7-yl)-methanone 
• 87707-11-7 7-hydroxy-benzoquinoline 
• 230-27-3 7,8-benzoquinoline 
• 853953-71-6 toluene-4-sulfonic acid 7-bromo-quinolin-8-yl ester 
• 521-74-4 broxyquinoline 
• 876-86-8 7-chloro-quinolin-8-ol 
• 36748-99-9 7-bromo-8-(methyloxy)quinoline 

Relevant articles and documents

Chemoselective synthesis of 5-amino-7-bromoquinolin-8-yl sulfonate derivatives and their antimicrobial evaluation

A series of new 5-amino-7-bromoquinolin-8-ol sulfonate derivatives 5(a–j) were synthesized from 8-hydroxyquinoline through multi-step process with high yields using mild, efficient and conventional methods. Chemoselectivity was observed during the transfo

A SAR study: Evaluation of bromo derivatives of 8-substituted quinolines as novel anticancer agents

Background: Brominated 8-hydroxy, 8-methoxy, 8-amino quinolines 5, 6, 8, 9 and novel cyano 8-hydroxyquinolines 11, 12 were evaluated in vitro for their anticancer effects on various cell lines. 5, 7-Dibromo- 5, 7-bromo- 6, 7-cyano- 11 and 5, 7-dicyano-12 8-hydroxyquinolines were shown to have strong antiproliferative activity against various tumor cell lines, including C6 (rat brain tumor), HeLa (human cervix carcinoma), and HT29 (human colon carcinoma) with IC50 values ranged from 6.7 to 25.6 μg/mL. Methods: A structure activity relationship (SAR) was conducted that quinoline core containing hydroxly group at C-8 positon led to more anti cancer potentials. Results: The results of Lactate Dehydrogenase (LDH) cytotoxic, DNA laddering and inhibition assays indicated that 5, 6, 11 and 12 have high cytotoxic effects and appototic potentials. Conclusion: Furthermore, 5 and 12 have inhibitory effects on relaxation of supercoiled plazmid DNA by supressed the Topoisomerase I enzyme. As a result, 5, 6, 11 and 12 may have promising anticancer drug potential and 5 and 12 may be novel topoisomerase inhibitors.

Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors

Certain aza- and polyaza-naphthalenyl ketones including certain quinolinyl and naphthyridinyl ketones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment or the delay in the onset of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.